Shares of BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $246.21.
A number of analysts have commented on BGNE shares. Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd.
Get Our Latest Stock Analysis on BeiGene
Insider Buying and Selling at BeiGene
Hedge Funds Weigh In On BeiGene
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of BeiGene during the third quarter valued at $36,000. Headlands Technologies LLC acquired a new position in BeiGene during the first quarter valued at $50,000. SG Americas Securities LLC purchased a new stake in BeiGene in the 3rd quarter worth about $105,000. Finally, Acadian Asset Management LLC lifted its stake in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after acquiring an additional 849 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.
BeiGene Stock Performance
BGNE stock opened at $205.04 on Tuesday. The company has a 50-day simple moving average of $212.41 and a 200 day simple moving average of $180.94. The company has a market capitalization of $19.96 billion, a P/E ratio of -40.36 and a beta of 0.63. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $248.16.
BeiGene Company Profile
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Featured Stories
- Five stocks we like better than BeiGene
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- 3 Healthcare Dividend Stocks to Buy
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.